Valeant’s Accounting Error a Warning Sign of Bigger Problems
Investors have other reasons to remain concerned about the accuracy of the company’s financial statements.
Showing posts with label Valeant’s. Show all posts
Showing posts with label Valeant’s. Show all posts
Tuesday, March 29, 2016
Valeant’s Accounting Error a Warning Sign of Bigger Problems
Sunday, October 4, 2015
Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers
Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers
A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.
Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers
Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers
A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.
Friday, October 2, 2015
Fair Game: Valeant’s High-Price Drug Strategy
Fair Game: Valeant’s High-Price Drug Strategy
Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company’s price increases.
Subscribe to:
Posts (Atom)